Genes Partly Predict Response to GLP-1 Weight-Loss Shots

Scientists analyzed data from 27,885 patients taking GLP-1 obesity drugs and found two gut-hormone gene variants may partly explain why weight loss and side-effects vary: rs10305420 is linked to slightly more weight loss, while rs1800437 is linked to nausea with tirzepatide. But the genetic contribution is modest; non-genetic factors like sex, drug type, dose, and duration explain much more of the variability, so genetics are not yet ready to guide routine treatment, though the findings could inform future precision approaches.